Phua Lee Cheng, Chue Xiu Ping, Koh Poh Koon, Cheah Peh Yean, Chan Eric Chun Yong, Ho Han Kiat
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore 117543, Republic of Singapore.
Department of Colorectal Surgery, Singapore General Hospital, Singapore 169856, Republic of Singapore.
Oncol Rep. 2014 Jul;32(1):97-104. doi: 10.3892/or.2014.3193. Epub 2014 May 16.
Fecal microRNAs (miRNAs) are increasingly explored as non-invasive markers of colorectal cancer (CRC). However, its holistic profile in Asian CRC patients remains elusive. In the present study, the global human fecal miRNAs in Asian Chinese CRC patients was assayed to elucidate novel diagnostic fecal markers. Additionally, the influence of blood in stool on fecal miRNA levels was investigated for the first time. Microarray analysis was applied to profile the fecal miRNAs extracted from CRC patients and healthy subjects. Concurrently, surgically resected tumor and matched normal mucosae were analyzed. Potential fecal miRNA markers were further confirmed using real-time PCR in 17 CRC patients and 28 healthy subjects. Global miRNA profiling uncovered 17 fecal markers (p<0.05) differentially regulated in CRC. Fecal miR-223 and miR-451 represented robust markers in distinguishing CRC patients from healthy subjects, as evident from areas under the receiver operator characteristic curves of 0.939 and 0.971, respectively. Blood in stool affected fecal miR-451, miR-223 and miR-135b levels to a varying extent and substantially impacted the interpretation of the clinical data. Notably, a discrete set of aberrant miRNAs occurred within the tumor, indicating the presence of contributors beyond the exfoliation of tumor cells to the fecal miRNA profile. In summary, the utility of a global miRNA screening approach was successfully demonstrated in elucidating diagnostic markers of CRC. In particular, fecal miR-223 and miR-451 hold promise in detecting CRC.
粪便微小RNA(miRNA)正越来越多地被探索作为结直肠癌(CRC)的非侵入性标志物。然而,其在亚洲CRC患者中的整体特征仍不清楚。在本研究中,对亚洲中国CRC患者的全球人类粪便miRNA进行了检测,以阐明新的诊断性粪便标志物。此外,首次研究了粪便中的血液对粪便miRNA水平的影响。采用微阵列分析对从CRC患者和健康受试者中提取的粪便miRNA进行分析。同时,对手术切除的肿瘤和匹配的正常黏膜进行分析。在17例CRC患者和28例健康受试者中,使用实时PCR进一步确认了潜在的粪便miRNA标志物。全球miRNA谱分析发现17种粪便标志物(p<0.05)在CRC中差异表达。粪便miR-223和miR-451是区分CRC患者和健康受试者的强有力标志物,分别从受试者操作特征曲线下面积为0.939和0.971可以明显看出。粪便中的血液在不同程度上影响粪便miR-451、miR-223和miR-135b水平,并对临床数据的解释产生重大影响。值得注意的是,肿瘤内出现了一组离散的异常miRNA,表明除了肿瘤细胞脱落对粪便miRNA谱有贡献外,还存在其他因素。总之,成功地证明了全球miRNA筛选方法在阐明CRC诊断标志物方面的实用性。特别是,粪便miR-223和miR-451在检测CRC方面具有前景。